Chemoradiotherapy or Chemotherapy Compared with Surgery in Patients with Gastric Cancer
the Cancer Therapy Advisor take:
Despite the phase I/II studies that have indicated that chemoradiotherapy could be beneficial, there has not yet been a statistically significant indication that preoperative radiotherapy with chemotherapy is beneficial to patients with gastric cancer.
Research recently published in the European Journal of Surgical Oncology summarized a literature review that aimed to compare survival and postoperative mortality and morbidity data in randomized clinical studies between patients who received preoperative chemoradiotherapy or chemotherapy versus surgery alone, or preoperative chemoradiotherapy versus chemotherapy for gastric and/or gastro-oesophageal junction (GOJ) cancer.
The researchers determined the hazard ratios for overall mortality and extracted the individual patient data from the principal investigators of each study or the study’s meta-analysis. Researchers also examined postoperative morbidity and mortality incidence of each study.
The researchers found 18 studies that matched the criteria they were searching and found that data was available from 14 studies. The hazard ratios in relation to the overall survival according to the meta-analysis was 0.75 (95% CI 0.65, 0.86, P<0.001) for preoperative chemoradiotherapy and 0.83 (95% CI 0.67, 1.01, P=0.065) for preoperative chemotherapy when compared with surgery alone. When preoperative chemoradiotherapy was compared directly to chemotherapy, the researchers found a hazard ratio of 0.71 (95% CI 0.45, 1.12, P=0.146).
There was no significant statistical difference between the risk for postoperative morbidity or mortality in preoperative treatments and surgery alone or preoperative chemoradiotherapy and chemotherapy.
However, there was a significant survival benefit for preoperative chemoradiotherapy for gastric cancer when compared with surgery alone and a trend towards improved survival after the addition of radiotherapy when comparing preoperative chemotherapy and chemoradiotherapy.
No statistically significant indication that preoperative radiotherapy is beneficial to patients with gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer